Quick Takeaways
- WASATCH ADVISORS LP filed SCHEDULE 13G/A for SANGAMO THERAPEUTICS, INC Common Stock (SGMO).
- Disclosed ownership: 5.2%.
- Date of event: 31 Mar 2025.
WASATCH ADVISORS LP - 31 Mar 2025 SCHEDULE 13G/A Report for SANGAMO THERAPEUTICS, INC Common Stock (SGMO)
- Filing Manager
- WASATCH ADVISORS LP
- Reporting Manager
- WASATCH ADVISORS LP
- Symbol
- SGMO
- Shares outstanding
- 223,666,750 shares
- Disclosed Ownership
- 11,630,671 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 May 2025, 17:32:23 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 07 Jan 2025
- Next filing
- 12 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"WASATCH ADVISORS LP disclosed 5.2% ownership in SANGAMO THERAPEUTICS, INC Common Stock (SGMO) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 07 Jan 2025.
- Current filing was accepted on 12 May 2025, 17:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 5.2% | 11,630,671 | 10,847,230 | 0 | Mike Yeates | CEO |